{"product_id":"jubilantpharmova-bcg-matrix","title":"Jubilant Pharmova Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eJubilant Pharmova’s BCG Matrix snapshot highlights a mix of established cash cows in mature contract manufacturing and high-potential question marks in specialty pharmaceuticals and R\u0026amp;D-driven segments—while a few low-growth units risk becoming dogs without strategic repositioning. This preview teases quadrant placements and strategic implications; purchase the full BCG Matrix to get quadrant-by-quadrant data, actionable recommendations, and downloadable Word and Excel files for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO Sterile Injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCDMO Sterile Injectables became a Star after Line 3 at Spokane went live in late 2025, nearly doubling capacity with a major U.S. government investment; this supports rising demand for biologics and sterile vials.\u003c\/p\u003e\n\u003cp\u003eSegment revenue jumped ~49% YoY by end-2025, driven by technology-transfer programs and stronger pricing; backlog rose to roughly $420m, positioning the unit to become a primary cash generator as clients favor U.S. sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePET Radiopharmacy Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova is investing $50 million to add six PET radiopharmacy sites in the U.S. by end-2025, aiming to become the #2 U.S. radiopharmacy network and win share in high-growth diagnostic hubs.\u003c\/p\u003e\n\u003cp\u003eThe shift from SPECT to PET targets higher-margin services; management expects new sites to exceed 20% EBITDA margins at optimal utilization, supporting a star classification in BCG.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRuby-Fill Cardiovascular Imaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRuby-Fill Cardiovascular Imaging drove a 37% rise in installations in 2025, lifting Radiopharmaceutical segment revenues by an estimated 28% year-over-year and expanding gross margins by ~450 basis points due to its high-margin pricing versus legacy tracers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRDMO Drug Discovery Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCRDMO Drug Discovery Services (Jubilant Biosys) is a Star in Jubilant Pharmova’s BCG matrix, driven by China Plus One demand as pharma shifts sourcing to India.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the segment posted double-digit revenue growth (≈12–18% y\/y) and sustained ~26% EBITDA margin, helped by a higher share of large-pharma contracts.\u003c\/p\u003e\n\u003cp\u003eJubilant integrated its API unit into CRDMO to deliver end-to-end discovery-to-manufacturing services and cut lead times.\u003c\/p\u003e\n\u003cp\u003eHigh global outsourcing growth and improved scale strengthen its competitive position and market share gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth: 12–18% y\/y by late 2025\u003c\/li\u003e\n\u003cli\u003eEBITDA margin: ~26%\u003c\/li\u003e\n\u003cli\u003eStrategy: China Plus One tailwinds\u003c\/li\u003e\n\u003cli\u003eIntegration: API into CRDMO for end-to-end\u003c\/li\u003e\n\u003cli\u003eOutlook: high outsourcing market growth, stronger competitive position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Therapeutics Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJubilant Pharmova’s specialty therapeutics pipeline, focused on radiopharmaceuticals like MIBG for neuroblastoma, is a Star: niche nuclear medicine with projected CAGR \u0026gt;12% to 2028 and limited competition.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Jubilant completed Phase 2 for MIBG, prepared an FDA submission package, and targets near-term commercial launch that could add $150–300M peak annual sales.\u003c\/p\u003e\n\u003cp\u003eThis unit has high barriers to entry—complex manufacturing, cold-chain logistics, and regulatory hurdles—supporting durable margins and market leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 2 complete (Dec 2025)\u003c\/li\u003e\n\u003cli\u003eFDA submission prepared (end-2025)\u003c\/li\u003e\n\u003cli\u003ePeak sales est $150–300M\u003c\/li\u003e\n\u003cli\u003eTheranostics market CAGR \u0026gt;12% to 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2025 Surge: CDMO +49% Growth, $420M Backlog, CRDMO 26% EBITDA, MIBG Phase 2 Win\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: CDMO Sterile Injectables, Radiopharma network expansion, CRDMO Drug Discovery, and Radiopharmaceutical therapeutics drove strong 2025 growth—segment rev +49% (CDMO), backlog ~$420M, CRDMO rev +12–18% y\/y with ~26% EBITDA, PET sites $50M capex targeting \u0026gt;20% EBITDA, MIBG Phase 2 done (Dec 2025) with $150–300M peak sales est.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2025 KPIs\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Sterile\u003c\/td\u003e\n\u003ctd\u003eRev +49% | Backlog $420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopharma\u003c\/td\u003e\n\u003ctd\u003e$50M capex | \u0026gt;20% EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRDMO\u003c\/td\u003e\n\u003ctd\u003eRev 12–18% | EBITDA ~26%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIBG\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Dec 2025 | Peak $150–300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Jubilant Pharmova: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Jubilant Pharmova units by market share\/growth for quick C-level decisions and print-ready sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllergy Immunotherapy (HollisterStier)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJubilant HollisterStier is the U.S. subcutaneous allergy immunotherapy market’s No.2 player, delivering stable, high‑margin sales and acting as the sole U.S. supplier of venom immunotherapy, a virtual monopoly in a mature clinical niche.\u003c\/p\u003e\n\u003cp\u003eThe segment generated strong cash flow with EBITDA margins of 35%–40% as of late 2025, funding Jubilant Pharmova’s capital‑intensive expansions in sterile injectables and radiopharmacies. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSPECT Radiopharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova’s SPECT radiopharmaceuticals, led by MAA and DTPA, hold a dominant U.S. share and generate steady, high margins; SPECT growth is single-digit vs PET’s double-digit, but SPECT still drives cash. The company’s 46 U.S. radiopharmacies supply over 1,800 hospitals, supporting ~60–70% gross margins on these SKUs in recent quarters. This cash cow provided roughly $120–160 million in annual EBITDA-like operating cash in 2024, funding debt service and R\u0026amp;D into next-gen nuclear medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadio-Iodine (Hicon I-131)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHicon I-131, Jubilant Pharmova’s market-leading radio-iodine therapy for hyperthyroidism and thyroid cancer, generates steady revenue—≈₹220–260 crore (2024 sales estimate)—and accounts for ~35–40% of Radiopharma EBIT in FY2024.\u003c\/p\u003e\n\u003cp\u003eIt sits in a mature, well-defined market with high entry barriers from radioactive handling rules and licensing, keeping competitive pressure low and margins high (~30–35% gross margin).\u003c\/p\u003e\n\u003cp\u003eMinimal incremental marketing spend is needed because of established clinician trust and long-term protocols, so Hicon I-131 remains a cash cow funding R\u0026amp;D and expansion across the Radiopharma portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing (CMO) Legacy Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe legacy sterile injectable lines at Spokane and Montreal run under long-term contracts with global innovators, averaging \u0026gt;90% utilization in 2024 and contributing roughly $35–45M EBITDA annually after depreciation.\u003c\/p\u003e\n\u003cp\u003eThese fully depreciated assets fund daily ops while growth shifts to Line 3; revenues are stable, with multi-year reorder rates \u0026gt;85% and predictable quarterly cash inflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh utilization: \u0026gt;90% (2024)\u003c\/li\u003e\n\u003cli\u003eAnnual EBITDA: $35–45M\u003c\/li\u003e\n\u003cli\u003eDepreciation: largely completed\u003c\/li\u003e\n\u003cli\u003eCustomer retention: \u0026gt;85% reorder rate\u003c\/li\u003e\n\u003cli\u003eRole: steady, predictable cash for ops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Specialty Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJubilant Pharmova’s International Specialty Distribution—covering Europe, APAC, and LATAM—serves as a mature revenue base, generating steady cash flows from allergy and radiopharma portfolios after market entries through 2025; these regions contributed an estimated $110–130m in annualized revenues by Q4 2025, reducing reliance on U.S. sales.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the company expanded beyond its U.S. focus into multiple international markets, delivering low-growth, high-margin returns without heavy R\u0026amp;D spend; gross margins on specialty distribution averaged ~28% in 2025, supporting free cash flow.\u003c\/p\u003e\n\u003cp\u003eThis global footprint functions as a Cash Cow: it leverages existing SKUs, established channels, and regulatory approvals to produce steady incremental growth while funding higher-risk projects like new drug R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegions: Europe, APAC, LATAM\u003c\/li\u003e\n\u003cli\u003e2025 revenue run-rate: ~$110–130m\u003c\/li\u003e\n\u003cli\u003eGross margin (2025): ~28%\u003c\/li\u003e\n\u003cli\u003eRole: low-R\u0026amp;D, steady cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJubilant’s cash cows fuel sterile‑injectable growth—$155–200M EBITDA backing R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJubilant’s cash cows—HollisterStier allergy immunotherapy, SPECT radiopharma, Hicon I‑131, legacy sterile injectables, and international specialty distribution—generated steady, high‑margin cash (EBITDA\/operating cash ≈$155–200M in 2024–25), funding sterile injectables expansion and R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024–25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHollisterStier\u003c\/td\u003e\n\u003ctd\u003eNo.2 US, 35–40% EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPECT radiopharma\u003c\/td\u003e\n\u003ctd\u003e46 sites, ~$120–160M cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHicon I‑131\u003c\/td\u003e\n\u003ctd\u003e₹220–260Cr sales; 35–40% Radiopharma EBIT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile injectables\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% util, $35–45M EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl distribution\u003c\/td\u003e\n\u003ctd\u003e$110–130M rev, ~28% gross\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eJubilant Pharmova BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Jubilant Pharmova BCG Matrix report you'll receive after purchase—no watermarks, no demo placeholders—just a fully formatted, analysis-ready file prepared for strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748215501177,"sku":"jubilantpharmova-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jubilantpharmova-bcg-matrix.png?v=1772206165","url":"https:\/\/matrixbcg.com\/products\/jubilantpharmova-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}